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CGRP, PACAP, and VIP Modulate Langerhans Cell
Function by Inhibiting NF-jB Activation
Wanhong Ding1, John A. Wagner2 and Richard D. Granstein1
The neuropeptides calcitonin gene-related peptide (CGRP), pituitary adenylate cyclase-activating polypeptide
(PACAP), and vasoactive intestinal peptide (VIP) suppress Langerhans cell (LC) antigen presentation and
modulate cytokine production. We have tested the hypothesis that these neuropeptides (NP) inhibit LC
function by modulating activation of NF-kB. Lipopolysaccharide (LPS) activates NF-kB in both a LC-like cell line
(XS52) and epidermal LC enriched to B95% and this effect is inhibited by each of the NP. Furthermore, CGRP,
PACAP, and VIP suppress phosphorylation of IkB kinase b (P-IKKb), prevent degradation of the IkBa, and inhibit
activation of NF-kB. Thus, these NP modulate LC function by reducing NF-kB activation. Bay 11-7085, an inhibitor
of IKK, reduced tumor necrosis factor-a (TNFa) production from LPS-stimulated XS52 cells and inhibited the
ability of LC to present antigen to a T-cell clone in vitro. Each NP also inhibited LPS-induced secretion of TNFa by
XS52 cells and LC enriched toB95% homogeneity. We suggest that the inhibitory activities of CGRP, PACAP, and
VIP on LC function are mediated, at least in part, by inhibition of P-IKKb, which prevents IkBa degradation and
activation of NF-kB. Modulation of this signaling pathway may be useful for therapeutic modulation of
immunity in the skin.
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INTRODUCTION
Langerhans cells (LC)3 are professional antigen-presenting
cells (APC) within the epidermis (Schmitt, 1999). They remain
in a relatively immature state until they are activated through
a series of events initiated by contact with an antigen. Until
recently, it was believed that, once activated, these cells
matured, took up and processed antigen, and migrated to
regional lymph nodes where they presented the processed
antigen to naive T cells, thereby initiating primary immune
responses (Steinman et al., 1995). Recently, a report utilizing
conditional langerin knockout mice suggested that epidermal
LC may actually downregulate the induction of cutaneous
immunity (Kaplan et al., 2005). Although this possibility
remains controversial, our previously reported observations
that epidermal nerves lie in close proximity to LC (Hosoi
et al., 1993) might suggest that release of inhibitory
neuropeptides (NP) by those nerves could prevent LC from
serving as effective APC (at least for T helper 1 responses) and
contribute to cutaneous immune regulation.
Vasoactive intestinal peptide (VIP) and the related peptide
pituitary adenylate cyclase-activating polypeptide (PACAP)
are, respectively, 28- and 38-amino acid peptides. They are
members of a superfamily of NP that includes secretin,
glucagon, and growth hormone-releasing hormone and bind
to an overlapping group of receptors. Two of these, VIP
receptor type 1 and VIP receptor type 2, bind PACAP, and
VIP with equal affinity. They are both G protein-coupled
receptors that activate adenylate cyclase with consequent
stimulation of cAMP production (Sherwood et al., 2000;
Laburthe et al., 2002). VIP, PACAP and their receptors have
been found in multiple organs, including the endocrine
system, the reproductive system, and the immune system
(Schulze et al., 1997; Odum et al., 1998; Mulder et al.,
1999). Studies have shown that PACAP and VIP have a
predominantly immunosuppressive effect on peritoneal
macrophages through regulation of cytokine production and
NF-kB activation (Delgado et al., 1999). Recently, we
demonstrated that treatment of epidermal cells with either
VIP or PACAP inhibited their ability to present antigen for
elicitation of delayed-type hypersensitivity in previously
immunized mice and intradermal administration of PACAP
inhibited the induction of contact hypersensitivity (CHS) at
the injected site. They also inhibited the ability of LC to
present antigen to a T helper 1 clone and augmented the
production of IL-10 by a lipopolysaccharide (LPS)-stimulated
LC-like dendritic cell line, while downregulating LPS-
stimulated IL-1b and IL-12 p40 production (Kodali et al.,
2003; Kodali et al., 2004).
Another particularly interesting peptide is calcitonin gene-
related peptide (CGRP), a 37-amino-acid peptide, widely
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distributed in multiple organs including the central and
peripheral nervous system and immune systems (Zaidi et al.,
1990). CGRP is co-expressed with ether somatostatin or
substance P in sensory neurons (Brain and Williams, 1988)
and is one of the major NP of the skin. We have reported that
treatment in vitro with CGRP inhibited the ability of LC to
stimulate allogeneic T cell and to present antigen to a T-cell
hybridoma in vitro (Hosoi et al., 1993), modulated LC
cytokine production and suppressed LC maturation (Torii
et al., 1997). In vitro treatment of epidermal cells also
inhibited their ability to present antigen for immunization of
mice by subcutaneous injection and intradermal administra-
tion of CGRP inhibited the induction of immunity to a hapten
painted at the injection (Asahina et al., 1995).
A more complete understanding of the molecular mechan-
isms through which PACAP, VIP, and CGRP attenuate LC
immune function would help explain how the nervous system
influences cutaneous immunity and may illuminate new
therapeutic approaches to the treatment of inflammatory skin
disorders. In this regard, the NF-kB transcription factor system
is of particular importance. In unstimulated cells, NF-kB
exists in an inactive state in the cytoplasm complexed with
the inhibitory protein IkB (Viatour et al., 2005). Upon cell
activation by various stimuli, including LPS and cytokine
stimulation, IkB kinase (IKK) becomes activated. IkBa then
undergoes phosphorylation and degradation and the NF-kB
heterodimer is translocated into the nucleus where it binds to
DNA and activates transcription (Li and Verma, 2002). A role
for NF-kB in various aspects of the immunobiology of APC
has been reported. NF-kB activation appears to be extremely
important in determining the functional development of APC
(Thomas et al., 2005). Inflammatory stimuli such as LPS,
tumor necrosis factor-a (TNFa), and IL-1 induce DC matura-
tion through the NF-kB pathway (Ardeshna et al., 2000). The
NF-kB family of transcription factors has multiple roles in
regulating events associated with differentiation of DCs and
presentation of antigen to T cells in lymphoid tissue (Pettit
et al., 1997; Ghosh et al., 1998), APC can mature via an
alternative NF-kB activation path independent of IkBa
degradation (Thomas et al., 2005). Importantly, elevated
NF-kB activation results in overall enhanced APC antigen
presentation function (Poligone et al., 2002; Sen et al., 2003).
Taken together, NF-kB activation appears to play a significant
role in stimulating antigen presentation. As NF-kB plays a
central role in regulating the transcription of proinflammatory
cytokines and co-stimulatory molecules (including CD80 and
CD86) important for antigen presentation (Rescigno et al.,
1998; Jeon et al., 1999; Feldmann et al., 2002), we asked
whether PACAP, VIP, or CGRP could regulate the activation
of this transcription factor. Furthermore, as production of
TNFa is tightly linked to NF-kB (Trede et al., 1995; Yao et al.,
1997), we also examined the influence of these NP on
induction of TNFa secretion as, if these NP inhibit NF-kB
activation, they should also inhibit induction of TNFa
secretion. The results of this study indicate that PACAP,
VIP, and CGRP suppress phosphorylation of IkB kinase b
(P-IKKb), prevent degradation of IkBa, and thus inhibit
activation of NF-kB. They also inhibit the induction of TNFa
secretion. These effects were observed in both a LC-like cell
line and fresh LC enriched to 95%.
RESULTS
PACAP, VIP, and CGRP inhibit LPS-induced NF-jB DNA
binding in XS52 cells
NF-kB is a transcriptional regulator involved in the expression
of co-stimulatory molecules and cytokines that facilitate
antigen presentation (Ardeshna et al., 2000; Rescigno et al.,
1998; Jeon et al., 1999; Feldmann et al., 2002). To test whether
the inhibitory effects of PACAP, VIP, and CGRP on LC function
might be mediated by NF-kB, we examined the effect of these
NP on LPS-stimulated NF-kB activation using an electrophore-
tic mobility shift assay. XS52 cells were cultured in the
presence or absence of PACAP, VIP, or CGRP for 1 hour and
then LPS was added to some cultures for 3 hours to activate
NF-kB. LPS caused a significant increase in NF-kB activation
(Figure 1a, lanes 1 vs 2), and this band was shifted by
incubation with antibody (Ab) to p50 or p65 (Figure 1a, lanes 3
and 4), demonstrating that we were measuring the authentic
transcription factor. PACAP, VIP, and CGRP each inhibited the
LPS-induced NF-kB activation (Figure 1a, compare lane 2 with
lanes 8, 9, and 10). To obtain a quantitative measure of the
degree of suppression observed, the gel from this experiment
and two others were analyzed by densitometry. The data in the
table in Figure 1a show the degree of suppression observed for
each NP in these three experiments. Thus, these NP inhibit NF-
kB activation. To begin to determine the site of this inhibition,
we measured the effect of the NP on the degradation of IkBa
and the activation of IKKb.
Figure 1. PACAP, VIP, and CGRP inhibit LPS-induced P-IKKb preventing IjB degradation and subsequent NF-jB nuclear translocation in XS52 and pLC.
(a) PACAP, VIP, and CGRP inhibit NF-kB DNA binding. XS52 cells were stimulated for 1 hour in the presence or absence of PACAP, VIP, or CGRP (108 M)
followed by addition of 1 mg/ml of LPS to some culture wells for 3 hours. Nuclear extracts were then prepared, probed, and used in the electrophoretic mobility
shift assay. For supershifting, nuclear extracts were incubated with polyclonal Abs against p50 or p65 for 10 minutes before the addition of the NF-kB probe. The
bar graph shows the density of the bands in the gel shown and the table shows the percent inhibition in each of three experiments. (b) PACAP, VIP, and CGRP
prevent degradation of IkBa in XS52 cells. XS52 cells were stimulated with 1mg/ml of LPS with or without the presence of PACAP, VIP, or CGRP (108 M). The
cytosolic amounts of IkBa at different time points were determined by immunoblot; equal amounts of protein were used to detect glyceraldehyde-3-phosphate
dehydrogenase as a control (lower panel). The bar graph shows the relative density of the bands in the gel shown and the table shows the percent of IkBa
degradation of three experiments. (c) PACAP, VIP, and CGRP reduced LPS-induced degradation of IkB in pLC. Fresh pLC from BALB/c mice were stimulated for
30 minutes with or without 1 mg/ml of LPS in the presence or absence PACAP, VIP, or CGRP (108 M). The cytosolic amounts of IkBa were detected by
immunoblotting; equal amounts of protein were used to detect IKKb to insure equivalent loading of protein (lower panel). The bar graph shows the relative
density of the bands in the gel shown and the table shows the percent of IkBa degradation of three experiments. (a, b, and c) One representative experiment of
three performed is presented.
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PACAP, VIP, and CGRP inhibit NF-jB nuclear translocation by
reducing LPS-induced degradation of IjBa in XS52 cells and LC
NF-kB activation is mediated by the phosphorylation and
degradation of IkBa (Viatour et al., 2005). To determine
whether PACAP, VIP, or CGRP prevent degradation of IkBa,
we exposed XS52 cells to 1 mg/ml of LPS in the presence or
absence of PACAP, VIP, or CGRP and measured IkBa by
immunoblotting. As expected, IkBa was degraded after the
cells were exposed to LPS stimulation (Figure 1b, top).
PACAP, VIP, and CGRP each reduced the degradation of
IkBa over time (5–60 minutes; Figure 1b). Glyceraldehyde-3-
phosphate dehydrogenase was measured to insure equivalent
loading of protein. In a separate experiment, in the absence of
LPS, no significant change in expression of IkBa was
observed over the time range examined (up to 60 minutes)
(data not shown).
To test whether these NP had a similar effect on authentic
LC, fresh purified LC (pLC) from BALB/c mice were cultured
in the complete medium (CM) supplemented with 10 ng/ml of
mGM-CSF for 1 hour. Some cultures were exposed to 1 mg/ml
of LPS in either the presence or absence of PACAP, VIP, or
CGRP (10 nM). Anti-IkBa immunoblots of cell extracts
prepared at 30 minutes showed that the each of the NP
reduced the LPS-induced degradation (Figure 1c). Thus,
PACAP, VIP, and CGRP inhibit LPS-stimulated IkBa degrada-
tion in both authentic LC and LC-like lines.
PACAP, VIP, and CGRP inhibit P-IKKb in XS52 cells and LC
Phosphorylation and activation of IKK promotes phosphory-
lation and degradation of IkB (Viatour et al., 2005), so we next
chose to determine if PACAP, VIP, or CGRP inhibit the
activation of IKK in both XS52 and authentic LC. Cultures of
XS52 cells (Figure 2a) and pLC (Figure 2b) were exposed to LPS
in the presence or absence of PACAP, VIP, or CGRP for
30 minutes as indicated. Thirty minutes of stimulation was
chosen as this yields the maximum expression of IKKa and IKKb
(data not shown). We measured P-IKKb by immunoblotting
using an Ab against the phosphorylated forms of IKKa/b. We
measured the level of total IKKb using an Ab that recognized
IKKb. LPS induced P-IKKb (Figure 2a, lane 1 vs 2), whereas
PACAP, VIP, and CGRP inhibit this P-IKKb in a dose-dependent
manner (Figure 2a, compare lane 2 with lanes 3, 4, 5, and 6).
Likewise, each of the three NP reduced LPS-dependent P-IKKb
in authentic pLC (Figure 2b). None of these peptides influenced
the absolute level of IKKb. In one of three experiments, P-IKKa
was inhibited by CGRP, PACAP, and VIP. In two of three
experiments, this was not observed with densitometry. How-
ever, in these two experiments, the bands for IKKa were very
light and it remains possible that these NP inhibit P-IKKa.
Bay 11-7085 inhibits LPS-induced P-IKKb in XS52 cells
Bay 11-7085 is an irreversible inhibitor of IkB phosphoryla-
tion (Pierce et al., 1997; Mabuchi et al., 2004). We examined
its ability to inhibit P-IKKb. XS52 cells were exposed to
1 mg/ml of LPS in the absence or presence of increasing
concentrations of Bay 11-7085 (0–10 mM) for 30 minutes. The
cytosolic content of P-IKKb was detected by immunoblotting.
LPS induced P-IKKa/b (Figure 3, lane 1 vs 2), whereas Bay 11-
7085 inhibited P-IKKb in a dose-dependent manner (Figure 3,
compare lane 2 with lanes 3, 4, 5, and 6). Thus, Bay 11-7085
inhibits P-IKKb.
NF-jB participates in antigen presentation by epidermal
LC to a T-cell clone
PACAP, VIP, and CGRP each inhibit antigen presentation by
LC (Hosoi et al., 1993; Kodali et al., 2003; Kodali et al.,
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Figure 2. PACAP, VIP, and CGRP suppress P-IKKb in both XS52 and freshly obtained epidermal LC. (a) PACAP, VIP, and CGRP suppressed P-IKKb in XS52
cells. Cultures of XS52 cells were exposed to 1 mg/ml LPS in the presence or absence of PACAP, VIP, or CGRP (107–10-11 M) for 30 minutes. Total protein was
then extracted and the amount of P-IKKb was determined by immunoblot using an Ab against both phosphorylated forms of IKK (P-IKKa and P-IKKb). Equal
amounts of protein were loaded into control wells to detect IKKb (lower panel). (b) PACAP, VIP, and CGRP inhibited P-IKKb in pLC. Fresh pLC from BALB/c mice
were cultured in 10 ng/ml of mGM-CSF for 1 hour. Then, they were stimulated for 30 minutes with or without 1 mg/ml of LPS in the presence or absence of
PACAP, VIP, and CGRP (108 M). Total protein was extracted and the amount of P-IKKb was determined by immunoblot. Equal amounts of protein were
loaded into control wells to detect IKKb. The bar graph shows the relative density of the bands in the gels shown and the table shows the percent of inhibition
of IKKb phosphorylation in three experiments. (a and b) One representative experiment of three performed is presented.
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2004), but it is not clear whether NF-kB activation is
important for antigen presentation by LC. To determine if
activation of NF-kB contributes to antigen presentation by
LC, we cultured epidermal cells (which are B2% LC) in the
absence or presence of increasing concentrations of Bay
11-7085, and then exposed them to keyhole limpet
hemocyanin (KLH) in the presence of the same concentration
of Bay 11-7085. Bay 11-7085 was carefully removed by
multiple washings, and the ECs were co-cultured with the
KLH-responsive T helper 1 clone, HDK-1, for 72 hours. We
measured IFN-g production by ELISA as an index of HDK-1
cell activation. Antigen-exposed ECs stimulated a significant
increase in IFN-g production, and this increase was inhibited
by Bay 11-7085 (Figure 4). This inhibition occurred with an
EC50 of about 0.6 mM, strongly suggesting that NF-kB
activation is central to antigen presentation by LC. The
ability of NP to inhibit NF-kB activation may be sufficient to
explain their effects on both TNFa expression and antigen
presentation.
NF-jB mediates LPS-dependent induction of TNFa
TNFa production is linked to NF-kB activation in several cell
types. We wished to confirm that this is the case in XS52
cells. We inhibited NF-kB activation with Bay 11-7085. XS52
cells were exposed to LPS in the presence or absence of Bay
11-7085 for 4 hours, and the amounts of TNFa production in
the culture supernatants were assayed by ELISA. LPS greatly
enhanced TNFa production, but Bay 11-7085 inhibited LPS-
induced TNFa production dose dependently (Figure 5a). In
additional experiments performed in the same manner,
supernatants were prepared from XS106 cells (chosen
because they produce high levels of IL-12 p40 and IL-1b)
and examined by ELISA for IL-12 p40 and IL-1b content. As
shown by the data in Figure 5b, Bay 11-7085 also potently
inhibited the induction of IL-12 p40 and IL-1b. As PACAP,
VIP, and CGRP inhibit the activation of IKK and NF-kB
activation, they should also inhibit the production of TNFa,
so we next examined this hypothesis.
PACAP, VIP, and CGRP inhibit LPS-induced TNFa production
in both XS52 cells and pLC
As production of TNFa is tightly linked to NF-kB activation,
we next examined the effect of PACAP, VIP, and CGRP on
TNFa secretion. XS52 cells were stimulated with different
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concentration of LPS in the absence or presence of various
doses of PACAP, VIP, or CGRP. We assayed the TNFa content
of culture supernatants by ELISA at different time periods. LPS
induced the production of TNFa within 90 minutes, and
PACAP, VIP, and CGRP each inhibited the induction of TNFa
production at each time point tested (Figure 6a). Inhibition of
TNFa production by PACAP, VIP, and CGRP was significant
and dose-dependent over the concentration range of 1–100 nM
(Figure 6b), with maximal effects at 10 nM (Figure 6b).
PACAP, VIP, and CGRP inhibited TNFa production at all
concentrations of LPS tested (0.01–1,000 ng/ml) (Figure 6c).
Thus, PACAP, VIP, and CGRP inhibit the production of TNFa.
To determine whether NP also downregulate the induction
of TNFa in authentic epidermal LC, we prepared pLC from
BALB/c mice. Some cultures were exposed to LPS in the
presence or absence of each NP. PACAP, VIP, and CGRP
each inhibited LPS-induced TNFa production (Figure 7). We
conclude that PACAP, VIP, and CGRP reduce the induction
of TNFa by LPS in highly enriched preparations of LC. We
suggest that the ability of PACAP, VIP, and CGRP to reduce
the activation of IKK and NF-kB contributes significantly to
their ability to reduce antigen presentation, the expression of
TNFa, and, probably, other markers of LC maturation.
DISCUSSION
PACAP, VIP, and CGRP downregulate several aspects of LC
immune function, including antigen presentation and the
induction of IL-1b and IL-12 p40 (Hosoi et al., 1993; Torii
et al., 1997; Kodali et al., 2003, 2004). Indeed, suppression of
antigen presentation by PACAP, VIP, and CGRP has been
demonstrated in several different systems and models.
Additionally, injection of CGRP or PACAP intradermally into
mice inhibits the acquisition of CHS at the injected site.
As PACAP, VIP, and CGRP each inhibit antigen presenta-
tion by LC and inhibit the LPS-induced induction of IL-1b and
IL-12 p40 production, we hypothesized that the effect of
these agents on LC function may be through inhibition of
activation of NF-kB. The results described above strongly
support this hypothesis. Each agent suppressed phosphory-
lation of IKKb and inhibited the degradation of IkBa, thus
inhibiting activation of NF-kB. They also inhibit the induction
of TNFa secretion. We also employed the pharmacologic
inhibitor of NF-kB activation, Bay 11-7085, to determine its
ability to inhibit TNFa production and LC antigen presenta-
tion function. This agent irreversibly inhibits the phosphory-
lation of IkB (Pierce et al., 1997; Mabuchi et al., 2004) and
we found that it also inhibits the P-IKKb. Bay 11-7085
inhibited the activity of IKK, disrupting the NF-kB/IkB
regulatory pathway and decreased the ability of LC to present
antigen to a T-cell clone. Bay 11-7085 also inhibited TNFa
production from LPS-stimulated XS52 cells as well as IL-12
p40 and IL-1b production by XS106 cells. Without P-IKKa/b,
the NF-kB dimer is not released and is unable to translocate
into the nucleus where it can bind to promoter sites on DNA.
Thus, this pharmacologic NF-kB inhibitor strikingly mimics
the effects of PACAP, VIP, and CGRP in this system. The
effects of these NP on LC appear to be mediated, at least in
part, by inhibition of the NF-kB activation pathway. Three
hours of exposure of fresh LC to concentrations of Bay
11-7085 below 10 mM did not affect viability 24 hours later as
assessed by FACS analysis (data not shown).
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Figure 5. Bay 11-7085 inhibited TNFa, IL-12 p40, and IL-1b production by
XS52 cells. (a) XS52 cells were stimulated with 1 mg/ml of LPS in the presence
or absence of Bay 11-7985 (0–10 mM) for 4 hours. Supernatants were collected
and TNFa release was determined by ELISA. The data shown represent the
meanþ SD of results obtained in an experiment performed in three separate
plates prepared at the same time where each plate was used as a data point to
compute the average value (N¼ 3). Two completely separate experiments
were performed on separate days that yielded similar results. (b) In a separate
experiment supernatants were assayed for IL-12 p40 and IL-1b. Each result
represents the meanþ SD of results obtained in an experiment performed in
three separate plates prepared at the same time where plate was used as a
data point to compute the average value (N¼3). A completely separate
experiment was performed on a separate day that yielded similar results.
**Po0.01, ***Po0.001.
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Figure 6. PACAP, VIP, and CGRP inhibited TNFa production by LPS-stimulated XS52 cells. (a) XS52 cells (2.5 105 cells/ml) were exposed to 0.1 mg/ml of LPS
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(b) Dose–response for the inhibitory effect of PACAP, VIP, and CGRP on LPS-stimulated TNFa production. XS52 cells (2.5 105 cells/ml) were exposed to
0.1mg/ml of LPS in the presence of a range of concentration of PACAP, VIP, or CGRP (0–100 nM) for 4 hours. Supernatants were collected and assayed by
ELISA for TNFa production. (c) PACAP, VIP, and CGRP inhibited TNFa production over a range of LPS concentrations (0.01–1,000 ng/ml). XS52 cells were
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release was determined by ELISA. The data shown represent the meanþ SD of results obtained in an experiment performed in three separate plates prepared at
the same time where the average of wells in each plate was used as a data point to compute the average value. Two completely separate experiments were
performed on separate days that yielded similar results. *Po0.05, **Po0.01, ***Po0.001 (a, b, and c).
www.jidonline.org 2363
W Ding et al.
Neuropeptides and NF-kB
PACAP, VIP, and CGRP clearly inhibited TNFa production
by XS52 cells and pLC and transcriptional regulation of the
TNFa gene is also known to be regulated by NF-kB (Trede
et al., 1995; Yao et al., 1997). This is of considerable interest
as TNFa plays an important role in the promotion of LC
maturation (Caux et al., 1992) and antigen presentation
(Grabbe et al., 1992). TNFa is also a stimulator for the
migration of LC (Cumberbatch et al., 1999; Cumberbatch
et al., 2003). During the sensitization phase of CHS, contact
allergens stimulate epidermal cells to synthesize and release
proinflammatory cytokines such as TNFa and IL-1b, which in
turn promote LC migration from skin. Knockout mice lacking
the p75 TNFa receptor exhibited depressed LC migration and
reduced CHS response (Wang et al., 1997).
However, there is some controversy regarding the ability of
LC to produce TNFa. Although there are reports that highly
enriched preparations of LC can make TNFa (Caux et al.,
1992, Fujita et al., 2005), Schreiber et al. (1992) stated that LC
likely do not produce significant amounts of TNFa and that
apparent TNFa production in highly enriched LC populations
is probably coming from contaminating keratinocytes. How-
ever, other investigators have reported that dendritic LC
generated from human cord blood produced TNFa, both
spontaneously and after stimulation with CD40 (de Saint-Vis
et al., 1998). Our results indicate that PACAP, VIP, and CGRP
inhibited LPS-induced TNFa production in a dose-dependent
manner in both XS52 cells and 95% LC from 107 to 1010 M,
with the maximum effect being observed at 108 M. As XS52 is
a cell line, the effect would seem to be certain in that system.
We cannot exclude the possibility that with a 95% LC
population, production of TNFa is actually from a few
contaminating keratinocytes with the locus of inhibitory
activity of the NP for TNFa at the keratinocyte. We also
recognize that as XS52 is a transformed dendritic cell line, its
ability to produce TNFa may be quite different from that of LC
in situ. Additionally, it is possible that the cell biology of LC
may be altered by the procedures needed to isolate them.
The ability of NP to inhibit NF-kB activation may explain,
at least in part, their effects on both cytokine expression and
antigen presentation. Additionally, the recent report that LC
may downregulate hypersensitivity in the skin may have
relevance to our findings. Kaplan et al. (2005) recently
reported on transgenic mice in which the regulatory elements
from human langerin were used to drive expression of
diphtheria toxin. These mice lacked epidermal LC but were
otherwise intact. It was found that these mice had enhanced
CHS responses and that the LC exerted their regulatory effect
in the priming phase of CHS (Kaplan et al., 2005). Two other
reports of mice in which the diphtheria toxin receptor gene is
‘‘knocked-in’’ to the langerin locus are relevant to this
discussion (Bennett et al., 2005; Kissenpfennig et al., 2005).
In this model, injection of mice with diphtheria toxin leads to
a loss of langerinþ cells. In one of these reports, a significant
decrease in CHS was observed with loss of LC (Bennett et al.,
2005), whereas in the other (Kissenpfennig et al., 2005), there
was no significant change in the CHS reponse. The reasons
for these discordant results are not clear, although Kaplan
et al. (2005) speculate that it may relate to the sparing of
spleen and lymph node langerinþ cells with their technique.
If it is true that LC are downregulatory for CHS response in the
skin, we speculate that, as many LC are in close approxima-
tion with epidermal nerves (Hosoi et al., 1993), nerve-derived
NP may contribute to this phenomenon by keeping LC in a
relatively immature state.
A more complete understanding of how NP such as
PACAP, VIP, and CGRP regulate LC function may reveal
insights that lead to novel approaches to the treatment of skin
disorders characterized by abnormal immune reactivity.
Furthermore, if the conditions of the release of these factors
were regulated by psychologic state, these findings may help
to explain how psychologic state could influence cutaneous
immunity.
MATERIALS AND METHODS
Mice
Female BALB/c (H-2d) mice (6- to 12-week-old) were purchased
from the Jackson Laboratory (Bar Harbor, ME). The mice were kept in
the animal facility of Weill Medical College of Cornell University on
a 12 hour light/dark cycle. All experiments using mice were
reviewed and approved by the Weill Cornell Institutional Animal
Care and Use Committee.
Reagents
Rat PACAP6–38, VIP, and CGRP were purchased from Peninsula
Laboratories (San Carlos, CA); LPS and Bay11 7085 was purchased
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Figure 7. CGRP, PACAP, and VIP inhibited TNFa production by
LPS-stimulated fresh pLC. Fresh pLC from BALB/c mice were cultured in
CM containing 10 ng/ml of mGM-CSF for 1 hour and then stimulated
with or without 0.1 mg/ml of LPS in the presence or absence of 10 nM CGRP,
PACAP, or VIP. Supernatants were collected after 6 hours of stimulation and
assayed for TNFa content by ELISA. The data shown represent the meanþ SD
of results obtained in an experiment performed in three separate plates
prepared at the same time where the average of wells in each plate was used
as a data point to compute the average value. Two completely separate
experiments were performed on separate days that yielded similar results.
*Po0.05, **Po0.01, ***Po0.001.
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from Sigma-Aldrich (Saint Louis, MO); rabbit monoclonal anti-IkBa
and anti-phosphorylated IKKa/IKKb Ab were purchased from Cell
Signaling Technology (Beverly, MA); anti-p50 and anti-p65 Ab were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell line and cell culture
CM consisted of Roswell Park Memorial Institute 1640 medium
(Cellgro, Herndon, VA) containing 10% fetal calf serum (Gemini
Bio-Products, Woodland, CA), 100 U/ml penicillin, 100 mg/ml
streptomycin, 0.1 mM nonessential amino acids, 0.1 mM essential
amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, and 10 mM
N-2-hydroxyethylpiperazine-N0-2-ethanesulfonic acid buffer (all CM
components were purchased from Mediatech (Herndon, VA).
For preparation of conditioned supernatants, cells were cultured
in CM with addition of 2 ml of phosphate-buffered saline (PBS)
containing a NP and the same volume of PBS was added to each
control well.
The XS52 and XS106 cell lines were generously supplied by A
Takashima (University of Texas, Southwestern Medical Center,
Dallas, TX). They are LC-like lines derived from neonatal
BALB/c (Xu et al., 1995) and A/J epidermis (Kodali et al., 2004),
respectively, that are dendritic in nature, capable of antigen
presentation, and have many phenotypic characteristics of LC
(Takashima et al., 1995; Xu et al., 1995). XS52 cells were grown
in CM with the addition of 2 ng/ml murine rGM-CSF (Chemicon
International, Temecula, CA), 10% NS cell supernatant (supernatant
conditioned by a fibroblast-like cell line, known to support the
growth of epidermal APC-derived cell lines (Pierce et al., 1997), and
5 105 M 2-ME (Sigma-Aldrich, St Louis, MO) at 371C in a
humidified incubator with 5% CO2.
The HDK-1 cell line, a KLH-specific, I-Ad-restricted T helper 1
clone, was also provided by A Takashima. It was maintained in CM
supplemented with 5 105 M 2-ME and 200 U/ml murine IL-2
(Chemicon Internation).
Preparation of purified epidermal LC
A preparation of LC enriched to approximately 95% homogeneity
was prepared as previously described (Seiffert et al., 2002). Briefly,
truncal skins of mice were shaved with an electric clipper and
remaining hairs were depleted with sodium thioglycolate (Nair,
Carter-Wallace, New York, NY). The subcutaneous fat and carnosus
panniculus were removed by blunt dissection. The skins were then
floated dermis-side down for 45 minutes in Caþ 2/Mg2þ -free PBS
containing 0.5 U of dispase/ml (Boehringer Mannheim, Indianapolis,
IN) and 0.38% trypsin (Sigma-Aldrich). Epidermal sheets were
removed with fine forceps and washed in PBS three times to remove
any dermal cell contamination. Epidermal cells were dissociated by
continuous mild agitation for 20 minutes in HBSS (Mediatech)
supplemented with 2% fetal calf serum. The epidermal cells were
then filtered through a 40-mm nylon gauge (BD Biosciences, Franklin
Lakes, NJ) and washed twice in CM.
To prepare pLC, epidermal cells were incubated in a 1/2,000
dilution of Thy-1.2 Ab (Sigma-Aldrich) for 30 minutes at 41C. The
cells were then washed twice and incubated in a 1/40 dilution of low
toxicity H-rabbit complement (Cederlane Laboratories, Hornby,
Canada) for 30 minutes at 371C. The cells were then washed twice
in PBS and incubated in PBS with 80 mg/ml DNase I (Sigma-Aldrich)
and 0.05% trypsin for 4 minutes at room temperature. The cells were
finally washed in CM (this procedure enriches for LC content by
selectively removing epidermal T cells and some keratinocyte), and
were incubated with anti I-Ad monoclonal Ab (BD PharMingen,
San Jose, CA) at a 1/50 dilution for 30 minutes at 41C with gentile
agitation. They were then incubated with goat anti-mouse IgG
conjugated to magnetic microspheres (Dynabeads M-450; Dynal
Biotech, Lake Success, NY) for 10 minutes with continuous gentle
agitation. The pLC were obtained by repeatedly washing (up to six
times) using a magnetic particle concentrator (Dynal Biotech, Lake
Success, NY). By FACS analysis using anti-I-Ad mAb, this procedure
yields a cell population of 92–98% LC (pLC).
Preparation of nuclear extracts
XS52 cells were plated at a density of 5 106 cells/plate in 25 cm2
tissue culture dishes, cultured in CM for 24 hours, then
stimulated with or without LPS in the presence or absence of NP
for 3 hours and washed twice with ice-cold PBS. Cell pellets were
homogenized with 400 ml of cell lysis buffer (10 mM N-2-hydroxy-
ethylpiperazine-N0-2-ethanesulfonic acid, pH 7.9, 10 mM KCl,
0.1 mM EDTA, 0.1 mM EGTA, 0.5 mM dithiothreitol, 0.5 mM phenyl-
methylsulfonyl fluoride, 10 mg/ml aprotinin, 10 mg/ml leupeptin,
10 mg/ml pepstatin, 5 mM NaF, 1 mM Na3VO4, and 1 mM NaN3).
After a 10 minute ice bath, Nonidet P-40 was added to a final
concentration of 0.5% and nuclei were isolated by centrifugation at
10,000 g for 1 minutes. Pelleted nuclei were lysed by incubation
for 30 minutes on ice in 50 ml of nuclear lysis buffer (20 mM N-2-
hydroxyethylpiperazine-N0-2-ethanesulfonic acid, pH 7.9, 420 mM
NaCl, 0.2 mM EDTA, 0.2 mM EGTA, 1.5 mM MgCl, 40 mM KCl, 25%
glycerol, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl, and
1mg/ml lepeptin) with agitation. Supernatants containing nulear
protein were harvested by centrifugation for 15 minutes at
12,000 g at 41C, the protein concentration was determined and
aliquots were stored at 801C.
Electrophoretic mobility shift assay
A double-stranded oligonucleotide containing an NF-kB binding site
derived from the nucleotides 85 to 76 of the murine inducible
nitric oxide synthase promoter was prepared as described (Xie et al.,
1994) and was kindly provided by A Ding (Weill Medical College
of Cornell University, New York, NY). The sequence is as follows
(NF-kB binding site is underlined):
50-gaagctTGGGGACTCTCCCTTTG
ACCCCTGAGAGGGAAACCCTT
The probe was labeled by Klenow polymerase using [a32P] dCTP
to a specific activity of 0.3–1.0 106 c.p.m./ng. Five microgram of
nuclear extracts from each test were incubated with the labeled
oligonucleotide probe (2–4 104 c.p.m.) in 15ml of reaction mixture
containing 20 mM N-2-hydroxyethylpiperazine-N 0-2-ethanesulfonic
acid (pH 7.9), 1 mM EDTA, 60 mM KCL, 12% glycerol, 1 mM
dithiothreitol, 2mg poly (dI–dC) at room temperature for 20 minutes.
Then, the samples were loaded onto 4.8% nondenaturing poly-
acrylamide gel and electrophoresed in Tris-borate-EDTA buffer
(45 mM Tris-HCl, pH 8.4, 1 mM EDTA, 45 mM boric Acid) at 41C,
followed by drying of the gel and autoradiography. In competition
and Ab supershift experiments, nuclear extracts were incubated for
15 minutes at room temperature with 1mg of anti-rabbit polyclonal
anti-p50 and 1mg of anti-rabbit polyclonal anti-p65 (Santa Cruz
Biotechnology) before the addition of the labeled probe.
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Detection of IjBa and P-IKKa/b protein
P-IKKa/b and IkBa were detected by Western blotting with Abs
specific to P-IKKa/b and IkBa. Two million XS52 cells per well in a
six-well plate were cultured in CM for 24 hours, and then stimulated
with or without LPS in the absence or presence of NP for 30 seconds.
Fresh pLC were cultured in CM with 10 ng/ml of mGM-CSF for
1 hour, and then stimulated with or without LPS in absence or
presence of NP for 30 seconds. After washing two times with cold
PBS, both of XS52 cells and pLC in each well were lysed by adding
250ml of cell lysis buffer (20 mM Tris-HCL, pH 7.5; 150 mM NaCl;
1 mM Na2EDTA; 1 mM EGTA; 1% Triton; 2.5 mM sodium pyropho-
sphate; 1 mM glycerophosphate; 1 mM NaVO4; 1mg/ml lepeptin,
1 mM phenylmethylsulfonylfluoride). Cells were then sonicated for
15 seconds and microcentrifuged for 5 minutes. The protein con-
centration in each sample was quantitative by the bicinchoninic acid
assay. Twenty-five micrograms of cell lysates were separated on a
7.5% SDS-PAGE gel and then electrotransfered to a nitrocellulose
membrane. The membrane was blocked with 5% nonfat dry milk in
Tris-buffered saline buffer with 0.1% Tween-20 for 1 hour and then
incubated with 1:1,000 diluted of rabbit anti-mouse P-IKKa/b and
IkBa Ab (Cell Signaling, Beverly, MA) overnight at 41C. The
membrane was washed three times and incubated with horseradish
peroxidase-conjugated goat anti-rabbit IgG (1:3,000 dilution) for
1 hour, and proteins were detected by a chemiluminescence
detection system (Amersham, Piscataway, NJ).
Densitometry
The relative density of bands in Western blots was analyzed using a
World Wide Web-based image processing system (ImageJ, http://
rsb.info.nih.gov/ij/) to obtain densities in arbitrary units (AU).
To obtain the percent inhibition of NF-kB activation observed
due to a NP, the following formula was used: [1(AUNPþ LPSAUNP)/
(AULPS–AUMED)]  100 where AUNPþ LPS is the value of a band
resulting from treatment with the NP and LPS, AUNP is the value
from treatment with the NP alone, AULPS is the value from treatment
with LPS alone, and AUMED is the value from treatment with medium
alone.
To obtain the percent of IkBa degradation observed in response
to LPS with and without the presence of NP, the following formula
was used. For Figure 1b: [1(A1/K1CA2/K2)] 100 where A1 is the
density of a band for IkBa after treatment at each time point, K1 is the
density of the corresponding band for glyceraldehyde-3-phosphate
dehydrogenase at each time point, A2 is the density of the band for
LPS stimulation at time 0, and K2 is the corresponding band for
glyceraldehyde-3-phosphate dehydrogenase at time 0. For Figure 1c:
[1(A1/K1CA2/K2)]  100 where A1 is the density of a band for IkBa
after treatment, K1 is the density of the corresponding band for IKKb
after treatment with LPS plus a NP, A2 is the density of the band
without LPS stimulation, and K2 is the corresponding band for IKKb
without LPS stimulation.
To obtain the percent inhibition of P-IKKb observed due to a NP,
the following formula was used. For Figures 2a and 3: [1(P1/K1
P2/K2)C(P3/K3P2/K2)] 100 where P1 is the density of a band for
P-IKKb after treatment at each concentration of NP, K1 is the density
of the corresponding band for IKKb, P2 is the density of the band
without stimulation, and K2 is the corresponding band for IKKb, P3 is
the density of the band for P-IKKb after treatment with LPS but
no NP and K3 is the corresponding band for IKKb. For Figure 2b:
[1(P1/K1P2/K2)C(P3/K3P2/K2)] 100 where P1 is the density of a
band for P-IKKb after treatment with LPS and a NP, K1 is the density
of the corresponding band for IKKb, P2 is the density of the band
without LPS stimulation, and K2 is the corresponding band for IKKb,
P3 is the density of the band for P-IKKb after treatment with LPS but
no NP and K3 is the corresponding band for IKKb.
Cytokine determination
The TNFa level in supernatants was detected by using murine TNFa,
IL-12 p40, and IL-1b sandwich ELISA kits (R&D systems, Minnea-
polis, MN) following the manufacturer’s instructions. IFNg produc-
tion by HDK-1 cells was analyzed by OptEIA sets of capture Ab and
biotinylated detection mAb for murine IFN-g (BD Pharmingen). One
hundred microliters of capture Ab (4mg/ml in coating buffer) was
added to each well in 96-well, flat-bottom plates and incubated
overnight at 41C. Then each well was aspirated and washed three
times with PBS-Tween 20 (0.05%). Wells were blocked with 200 ml
of 10% fetal bovine serum in PBS, followed by aspirating and
washing each well three times with PBS-Tween 20 (0.05%). One
hundred microliters of each standard and sample were then added to
wells. After incubation at room temperature for 2 hours, each well
was aspirated and washed five times with PBS-Tween 20 (0.05%).
Then 100ml of detection Ab (1mg/ml) was added to each well,
followed by incubation at room temperature for 1 hour. Wells were
aspirated and washed five times with PBS-Tween 20 (0.05%). Then,
100ml of avidin-horseradish peroxidase (1/2,000) was added to each
well, followed by incubation for 30 minutes at room temperature.
After aspiration and washing of each well seven times with PBS-
Tween 20 (0.05%), 100 ml of substrate solution (tetramethylbenzi-
dine and hydrogen peroxide) was added to each well at room
temperature in the dark. Fifty microliters of 1 M H3PO4 was added to
each well to stop the reaction, and wells were read at 450 nm.
Statistical analysis
The significance of differences among groups was measured by
Students’ two-tailed t-test for unpaired samples (Excel software;
Microsoft, Seattle, WA).
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